Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
11 April 2023 - 7:23AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2023
Commission File Number: 001-39137
AnPac Bio-Medical
Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS
FORM 6-K REPORT
On April 10, 2023, AnPac Bio-Medical
Science Co., Ltd. (the “Company”) engaged Zhong Yin Law Firm as the Company’s legal counsel with respect to laws
of the People’s Republic of China (the “PRC”, which, for the purposes of
this report, excludes the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan). Effective
April 10, 2023, Zhong Lun Law Firm will no longer serve as the Company’s PRC legal Counsel.
SIGNATURES
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. |
|
|
|
By: |
/s/Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Co-Chief Executive Officer |
|
|
|
Dated: April 10, 2023 |
|
|
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024